Page 83 - 《中国药房》2024年20期
P. 83

管纳入患者未使用负荷剂量的左西孟旦,但其剂量仍偏                                and septic shock:sepsis-3[J]. JAMA,2016,315(8):801-810.
          高[最新的一项 Meta 分析结果显示,脓毒症患者使用左                       [ 9 ]  BOISSIER F,AISSAOUI N. Septic cardiomyopathy:diag‐
                                             [20]
          西孟旦的最佳剂量应为 0.1 μg/(kg·min) ]。(3)本研究                     nosis and management[J]. J Intensive Med,2022,2(1):
          为阴性结果,可能与样本量较小有关。                                       8-16.
                                                             [10]  HERPAIN A,BOUCHEZ S,GIRARDIS M,et al. Use of
              综上所述,对于经充分液体复苏、MAP≥65 mmHg
                                                                  levosimendan  in  intensive  care  unit  settings:an  opinion
          且接受PiCCO监测的感染性休克合并心肌抑制患者,左
                                                                  paper[J]. J Cardiovasc Pharmacol,2019,73(1):3-14.
          西孟旦在改善心脏功能和血流动力学方面的作用与多
                                                             [11]  RHODES A,EVANS L E,ALHAZZANI W,et al. Survi-
          巴酚丁胺相当,且不会影响患者预后,也不会增加低血
                                                                  ving sepsis campaign:international guidelines for manage‐
          压等不良反应的发生风险。鉴于左西孟旦易获得,其治                                ment  of  sepsis  and  septic  shock:2016[J].  Intensive  Care
          疗成本与多巴酚丁胺大致相当,故临床可考虑选用。本                                Med,2017,43(3):304-377.
          课题组后续拟开展更大样本量的临床研究以进一步探                            [12]  刘红娟,耿静,何志红,等. 左西孟旦治疗脓毒症心肌抑
          索左西孟旦在感染性休克合并心肌抑制患者中的临床                                 制的疗效及对心功能的影响[J]. 临床内科杂志,2020,37
          应用价值。                                                  (6):447-448.
          参考文献                                                    LIU H J,GENG J,HE Z H,et al. Effect of levosimendan
          [ 1 ]  田文龙,程红颖,董士民. 左西孟旦治疗严重脓毒症及脓                       on myocardial inhibition and cardiac function in sepsis[J].
              毒症休克的临床疗效的 Meta 分析[J]. 临床荟萃,2018,                   J Clin Intern Med,2020,37(6):447-448.
                                                             [13]  PAN  J,YANG  Y  M,ZHU  J  Y,et  al.  Multiorgan  drug
              33(7):562-567.
                                                                  action of levosimendan in critical illnesses[J]. Biomed Res
              TIAN W L,CHENG H Y,DONG S M. Meta analysis of
                                                                  Int,2019,2019:9731467.
              levosimendan  in  treatment  of  severe  sepsis  and  septic
              shock[J]. Clin Focus,2018,33(7):562-567.       [14]  OSPINA-TASCÓN G A,CALDERÓN-TAPIA L E. Inodi‐
                                                                  lators  in  septic  shock:should  these  be  used? [J].  Ann
          [ 2 ]  LIU D H,NING Y L,LEI Y Y,et al. Levosimendan ver‐
                                                                  Transl Med,2020,8(12):796.
              sus dobutamine for sepsis-induced cardiac dysfunction:a
                                                             [15]  YANG F,ZHAO L N,SUN Y,et al. Levosimendan as a
              systematic review and meta-analysis[J]. Sci Rep,2021,11
                                                                  new force in the treatment of sepsis-induced cardiomyopa‐
              (1):20333.
                                                                  thy:mechanism and clinical application[J]. J Int Med Res,
          [ 3 ]  EVANS  L,RHODES A,ALHAZZANI  W,et  al.  Survi-
              ving sepsis campaign:international guidelines for manage‐  2019,47(5):1817-1828.
                                                             [16]  ZANGRILLO A,PUTZU A,MONACO F,et al. Levosi‐
              ment  of  sepsis  and  septic  shock  2021[J].  Intensive  Care
                                                                  mendan  reduces  mortality  in  patients  with  severe  sepsis
              Med,2021,47(11):1181-1247.
                                                                  and septic shock:a meta-analysis of randomized trials[J].
          [ 4 ]  SHEN X D,ZHANG H S,ZHANG R,et al. Progress in
                                                                  J Crit Care,2015,30(5):908-913.
              the  clinical  assessment  and  treatment  of  myocardial  de‐
                                                             [17]  GORDON A C,PERKINS G D,SINGER M,et al. Levosi‐
              pression in critically ill patient with sepsis[J]. J Inflamm   mendan for the prevention of acute organ dysfunction in
              Res,2022,15:5483-5490.
                                                                  sepsis[J]. N Engl J Med,2016,375(17):1638-1648.
          [ 5 ]  SANGALLI F,BELLANI G,AFFRONTI A,et al. Levosi‐
                                                             [18]  GUAN Q C,ZHANG C,LI B B,et al. Meta-analysis of
              mendan to facilitate weaning from cardiorespiratory sup‐
                                                                  the  efficacy  of  levosimendan  in  the  treatment  of  severe
              port  in  critically  ill  patients:current  evidence  and  future
                                                                  sepsis  complicated  with  septic  cardiomyopathy[J].  Heart
              directions[J]. Minerva Anestesiol,2020,86(6):645-651.
                                                                  Surg Forum,2023,26(5):E609-E620.
          [ 6 ]  FARMAKIS D,ALVAREZ J,BEN GAL T,et al. Levosi‐  [19]  PONIKOWSKI P,VOORS A A,ANKER S D,et al. 2016
              mendan beyond inotropy and acute heart failure:evidence
                                                                  ESC  guidelines  for  the  diagnosis  and  treatment  of  acute
              of pleiotropic effects on the heart and other organs:an ex‐  and chronic heart failure:the task force for the diagnosis
              pert  panel  position  paper[J].  Int  J  Cardiol,2016,222:  and  treatment  of  acute  and  chronic  heart  failure  of  the
              303-312.                                            European  Society  of  Cardiology (ESC)  developed  with
          [ 7 ]  PiCCO监测技术操作管理共识专家组. PiCCO监测技术                    the  special  contribution  of  the  Heart  Failure Association
              操作管理专家共识[J]. 中华急诊医学杂志,2023,32(6):                  (HFA)of the ESC[J]. Eur Heart J,2016,37(27):2129-
              724-735.                                            2200.
              Expert Group of Expert Consensus on Operation Manage‐  [20]  TAN R M,GUO H,YANG Z N,et al. Efficacy and safety
              ment of PiCCO Monitoring Technology. Expert consensus   of levosimendan in patients with sepsis:a systematic review
              on  operation  management  of  PiCCO  monitoring  techno-  and network meta-analysis[J]. Front Pharmacol,2024,15:
              logy[J]. Chin J Emerg Med,2023,32(6):724-735.       1358735.
          [ 8 ]  SINGER M,DEUTSCHMAN C S,SEYMOUR C W,et                     (收稿日期:2024-03-25  修回日期:2024-09-09)
              al. The third international consensus definitions for sepsis                        (编辑:张元媛)


          中国药房  2024年第35卷第20期                                              China Pharmacy  2024 Vol. 35  No. 20    · 2521 ·
   78   79   80   81   82   83   84   85   86   87   88